JOURNAL OF BACTERIOLOGY AND VIROLOGY ISSN:1598-2467(Print) 2093-0429(Online)

Clinical and labroatory institute. Performance standards for antimicrobial susceptibility tests. M200, 29^th ED. Wayne, PA.: Clinical and laboratory standards institute, 2019.

Satlin MJ, Nicolau DP, Humphries RM, Kuti JL, Campeau SA, Lewis JS, et al. Development of daptomycin susceptibility breakpoints for Enterococcus faecium and revisionof the breakpoints for other enterococcal species by the Clinical and Laboratory Standards Institute. Clin Infect Dis 2020;70:1240-6.

Bryant KA, Roberts AL, Rupp ME, Anderson JR, Lyden ER, Fey PD, et al. Susceptibility of enterococci to daptomycin is dependent upon testing methodology. Diagn Microbiol Infect Dis 2013;76:497-501.

Belley A, Lalonde-Séguin D, Arhin FF, Moeck G. Comparative pharmacodynamics of single-dose oritavancin and daily high-dose daptomycin regimens against vancomycin-resistant Enterococcus faecium isolates in an in vitro pharmacokinetic/pharmacodynamics model of infection. Antimicrob Agents Chemother 2017;61:e01265-17.

Humphries RM. The new, new daptomycin breakpoint for Enterococcus spp. J Clin Microbiol 2019;57:e00600-19.

Davlieva M, Wu C, Zhou Y, Arias CA, Shamoo Y. Two mutants commonly associated with daptomycin resistance in Enterococcus faecium LiaS (T120A), and LiaR (W73C) appear to function epistatically in LiaFSR signaling. Biochemistry 2018;57:6797-6805.

Sader HS, Jones RN. Impact of EUCAST, CLSI, and USCAST ceftaroline breakpoint changes on the susceptibility of methicillin-resistant Staphylococcus aureus isolates collected from US medical centers. (2015-2018). Clin Microbiol Infect 2020;26:658-9.

Ahmad O, Crawford TN, Myint T. Comparing the outcomes of ceftaroline plus vancomycin or daptomycin combination therapy versus monotherapy in adults with complicated and prolonged methicillin-resistant Staphylococcus aureus bacteremia initially treated with supplemental ceftaroline. Infect Dis Ther 2020;9:77-87.

Sader HS, Rhomberg PR, Doyle TB, Flamm RK, Mendes RE. Evaluation of the Revised ceftaroline disk diffusion breakpoints when testing a challenge collection of methicillin-resistant Staphylococcus aureus isolates. J Clin Microbiol 2018;56:e00777-18.

Jones RN, Flamm RK, Castanheira M, Sader HS, Smart JI, Mendes RE. Activity of telavancin against Gram-positive pathogens isolated from bone and joint infections in north American, Latin American, European, and Asia-pacific nations. Diagn Microbiol Infect Dis 2017;88:184-7.

Mendes RE, Farrell DJ, Sader HS, Streit JM, Jones RN. Update of the telavancin activity in vitro tested against a worldwide collection of Gram positive clinical isolates (2013), when applying the revised susceptibility testing method. Diagn Microbiol Infect Dis 2015;81:275-9.

Mendes RE, Farrell DJ, Sader HS, Jones RN. Oritavancin microbiologic features and activity results from the Surveillance Program in the United States. Clin Infect Dis 2012;54 Suppl 3:S203-13.

Belley A, Arhin F, Moek G. Oritavancin disk diffusion can distinguish vancomycin-intermediate Staphylococcus aureus from vancomycin-susceptible S. aureus. The medicines company, St-Laurent, QC, Canada, Poster #0713, Presented at ECCMID 2015 (25^th European Congress of Clinical Microbiology and infectious diseases) 25-28, April, 2015, Copenhagen, Denmark: 2015.

Clinical and laboratory institute. Performance Standards for Antimicrobial susceptibility tests 31th ed. Wayne, PA: Clinical and laboratory standards institute, 2021.

Huse HK, Miller SA, Chandrasekaran S, Hindler JA, Lawhon SD, Bemis DA, et al. Evaluation of oxacillin and cefoxitin disk diffusion and MIC breakpoints established by the clinical and laboratory standards institute for detection of mecA mediated oxacillin resistance in Staphylococcus schleiferi. J Clin Microbiol 2018;56:e01653-17.

Humphries RM, Magnano P, Burnham CA, Dien Bard J, Dingle TC, Callan K, et al. Evaluation of surrogate tests for the presence of mecA-mediated methicillin resistance in Staphylococcus capitis, Staphylococcus haemolyticus, Staphylococcus hominis, and Staphylococcus warneri. J Clin Microbiol 2020;59:e02290-20.

Paukner S, Gelone SP, Arends SJR, Flamm RK, Sader HS. Antibacterial activity of lefamulin against pathogens most commonly causing community-acquired bacterial pneumonia: SENTRY Antimicrobial Surveillance Program (2015-2016). Antimicrob Agents Chemother 2019;63:e02161-18.

Wu S, Zheng Y, Guo Y, Yin D, Zhu D, Hu F. In vitro activity of Lefamulin against the common respiratory pathogens isolated from Mainland China during 2017-2019. Front Microbiol 2020;11:578824.

Barros Dos Santos KT, Skaf LB, Justo-da-Silva LH, Medeiros RC, Francisco Junior RDS, Caniné MCA, et al. Evidence for clonally associated increasing rates of azithromycin resistant Neisseria gonorrheae in Rio De Janneiro, Brazil. Biomed Res Int 2019;2019:3180580.

Parmar NR, Singh R, Martin I, Perera SR, Demczuk W, Kusalik A, et al. Genomic analysis reveals antibiotic susceptible clones and emerging resistance in Neisseria gonorrheae in Saskatchewan, Canada. Antimicrob Agents Chemother 2020;64:02514-19.

Gianecini R, Irazu L, Rodríguez M, Cristaldo P, Oviedo C, Turco M, et al. Testing of in vitro susceptibility of Neisseria gonorrheae to Azithromycin: Comparison of disk diffusion and reference agar dilution methods. J clin microbiol 2020;58:e01398-20.

McAuliffe GN, Smith M, Cooper G, Forster RF, Roberts SA. Variability in azithromycin susceptibility results for Neisseria gonorrheae obtained using gradient MIC strip and agar dilution techniques. J Clin Microbiol 2019;57:e01353-19.

Campbell D, Bowen A, Bhatnagar A, McCullough A, Grass J, Chen J, et al. Identification and characterization of Shigella with decreased susceptibility to azithromycin in the United States, 2005-2014. J Glob Antimicrob Resist 2020;21:417-9.

Salah M, Shtayeh I, Ghneim R, Al-Qass R, Sabateen A, Marzouqa H, et al. Evaluation of Shigella species Azithromycin CLSI epidemiological cut off values and macrolide resitance genes. J Clin Microbiol 2019;57:e01422-18.

Performance standards for antimicrobial susceptibility tests. M100 27th ed. Wayne, PA: Clinical and laboratory standards institute, 2017.

Performance standards for antimicrobial susceptibility tests. M 100 30th ed. Wayne, PA: Clinical and laboratory standards institute, 2020.

Satlin MJ, Lewis JS, Weinstein MP, Patel J, Humphries RM, Kahlmeter G, et al. Clinical and laboratory standards institute and European committee on Antimicrobial susceptibility testing position statements on polymyxin B and colistin clinical breakpoints. Clin Infect Dis 2020;71:e523-9.

Poirel L, Kieffer N, Brink A, Coetze J, Jayol A, Nordmann P. Genetic features of MCR-1 producing colistin-resistant Escherichia coli isolates in South Africa. Antimicrob Agents Chemother 2016;60:4394-7.

Performance standards for antimicrobial susceptibility tests. M 100 , 28th ed, Wayne, PA: Clinical and laboratory standards institure, 2018.

Candel FJ, Santerre Henriksen A, Longshaw C, Yamano Y, Oliver A. In vitro activity of the novel siderophore cephalosporin, cefiderocol, in Gram-negative Pathogens in Europe by site of infection. Clin Microbiol Infect 2022;28:447.e1-e6.

EUCAST. Breakpoints for cefiderocol from EUCAST. 2020.

Food and drug administration center for drug center for For Drug Evaluation and Research. Final Summary minutes of the Antimicrobial drugs advisory committee meeting. 2019.

Yamano Y, Takemura M, Longshaw C, Echols R. Differences in interpretative breakpoints between CLSI, FDA and EUCAST Impact Reproting of susceptibility and resistance to cefiderocol. Open forum infectious diseases 2020;7:S651.

Simner PJ, Patel R. Cefiderocol antimicrobial susceptibility testing considerations: the Achilles' Heel of the Trojan Horse? J Clin Microbiol 2020;59:e00951-20.

Morris CP, Bergman Y, Tekle T, Fissel JA, Tamma PD, Simner PJ. Cefiderocol antimicrobial susceptibility testing against multidrug-resistant Gram-Negative bacilli: a comparison of disk diffusion to broth microdilution. J Clin Microbiol 2020;59:e01649-20.

Bleibtreu A, Dortet L, Bonnin RA, Wyplosz B, Sacleux SC, Mihaila L, et al. Susceptibility testing is key for the success of cefiderocol treatment: A retrospective cohort study. Microorganisms 2021;9:282.

Morris CP, Bergman Y, Tekle T, Fissel JA, Tamma PD, Simner PJ. Cefiderocol antimicrobial susceptibility testing against multidrug-resistant Gram-negative bacilli: a comparison of disk diffusion to broth microdilution. J Clin Microbiol 2020;59:e01649-20.

Bhowmick T, Weinstein MP. Microbiology of meropenem-vaborbactam: A novel carbapenem betalactamase inhibitor combination for carbapenem resistant Enterobacterales infections. Infect Dis Ther 2020;9:757-67.

Zhang J, Li G, Zhang G, Kang W, Duan S, Wang T, et al. Performance evaluation of the gradient diffusion strip method and disk diffusion method for ceftazidime-avibactam against Enterobacterales and Pseudomonas aeruginosa: A dual center study. Front Microbiol 2021;12:710526.

Sherry NL, Baines SL, Howden BP. Ceftazidime/avibactam susceptibility by three different susceptibility testing method in carbapenemase producing Gram negative bacteria from Australia. Int J Antimicrob Agents 2018;52:82-5.

Becka SA, Zeiser ET, Lipuma JJ, Papp-Wallace KM. Activity of imipenem-relebactam against multidrug- and extensively Drug-resistant B. cepacia complex and B. gladioli. Antimicrob Agents Chemother 2021;65:e0133221.

Shamsheyeva A, Oppermann N, Taku A, Ndobegang A, Gamage D, Chantell C, et al. Performance of 2019 CLSI ciprofloxacin breakpoint antimicrobial susceptibility testing algorithms for Enterobacteriaceae and Pseudomonas aeruginosa directly from positive blood culture on the Accelerate pheno system. Open forum infectious diseases 2019;6:S726-7.

Van TT, Minejima E, Chiu CA, Butler-Wu SM. Don't get woung up : Revised fluoroquinolone breakpoints for Enterobacteriaceae and Pseudomonas aeruginosa. J Clin Microbiol 2019;57:e02072-18.

Traczewski MM, Beasley D, Harrington A, DesJarlais S, Garner O, Hastey C, et al. Updated CLSI ciprofloxacin breakpoints from a multicenter assessment for Enterobacterales, Salmonella spp. and Pseudomonas aeruginosa using Microscan dried Gram negative MIC panels. Open forum infectious diseases 2020;7:S391.

Chu YW, Tse H, Tsang D. Adoption of the new CLSI fluoroquinolone breakpoints for Enterobacteriaceae. J Clin Microbiol 2019;57:e01176-19.